Across TCGA pan-cancer cohorts, TMEM91 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TMEM91 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher TMEM91 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM91 expression acts as an unfavorable survival marker.
BRCA and HNSC are the cancer types where TMEM91 Mutation most reproducibly stratifies survival.